Leadership

Senior Leadership

eNeura Board of Directors

  • David K. Rosen | President and Chief Executive Officer, eNeura, Inc.

    Dr. Rosen is a healthcare executive with over 20 years of experience in biotech, pharmaceuticals, and medical devices. Prior to joining eNeura, he was President and COO of Aratana Therapeutics,

    a pharmaceutical company he founded while Entrepreneur-in-Residence at MPM Capital. Prior to joining MPM Capital, he was the head of corporate out-licensing for Pfizer Inc. in New York, responsible for spinouts and divestitures of research and development programs and of commercial products. Between 2007 and 2010, he and his teams successfully created several pharma spinouts, including the formation of a venture capital-backed, 80-person life sciences company in Nagoya, Japan, and an anti-infectives company in New York. As the head of out-licensing, he led Pfizer’s efforts to divest of more than two dozen pharmaceutical development programs to both strategic buyers and financial investors.

    Dr. Rosen also serves on the board of directors of Ablative Solutions Inc., a medical device company focused on innovative treatments for chronic refractory hypertension, and is a Managing Director of Adjacent Health Technologies, a company focused on creating wellness by positively incentivizing individuals to become accountable for their health.

    Dr. Rosen received a Bachelor of Science degree from the University of Wisconsin, Madison, in Bacteriology and a Doctor of Veterinary Medicine degree from Iowa State University, College of Veterinary Medicine.

  • David R. Fischell | Chief Executive Officer, Angel Medical Systems

    Dr. David Fischell is a serial entrepreneur who has founded 14 biomedical device companies in the last 20 years, including Angel Medical Systems, developers of an implantable heart attack

    detection and patient alerting system; eNeura, Inc. (2002) Transcranial Magnetic Stimulation systems for Migraine Headaches; NeuroPace, Inc. (1997), implantable brain pacemakers to treat epilepsy and Ablative Solutions (2011) to develop chemical-based rental denervation catheters to treat hypertension.

    He currently has 156 issued U.S. patents, mostly medical devices, and from 1998 through 2003 was the primary designer of coronary stents, including the BX Velocity™ and Cypher™ Stents for Cordis now implanted in more than 7 million patients

  • Eileen O'Rourke | The Abell Foundation

    As Chief Financial Officer, Eileen has overall responsibilities for the business and investment operations of the Foundation. She is responsible for evaluating, structuring, negotiating, and

    managing direct investments in early stage companies and in program-related non-profit projects.Eileen actively participates with the management team in advancing commercialization of promising technologies, including the Foundation’s investment in OTEC International LLC. She is responsible for implementation and performance monitoring of the Foundation’s investment portfolio and cash management functions.

    Eileen has thirty years of experience in business finance and project management, with over a dozen years managing direct investments in early companies and in providing innovative financing solutions in support of social mission activities. She graduated summa cum laude from Loyola College and is a certified public accountant, a registered securities broker, and a certified financial and operations principal.  A former KPMG Manager and Vice-President with Legg Mason Inc., Eileen represents the Foundation on the board of directors of its investments in eNeura, Pixelligent, and Ceratech and on the Investment Committee of the Propel Baltimore Fund in which the Foundation is a limited partner.  She is also on the board and finance committee of the Everyman Theatre. She enjoys the many cultural and outdoors activities in Baltimore with her husband and two children.

  • Jacob Vogelstein | Partner and Portfolio Manager, Camden Partners Holdings

    Jacob Vogelstein is a Partner and Portfolio Manager at Camden Partners Holdings, LLC, where he focuses on Camden’s seed strategy. He currently serves on the board of Cage Pharmaceuticals,

    eNeura, Mind-X and Metabolon.

    Prior to joining Camden, Jacob was a founding partner of the seed-stage venture capital firm Gamma 3, LLC, and a Program Manager at the Intelligence Advanced Research Projects Activity, where he made investments in high-risk, high-reward research to benefit the US Intelligence Community. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, in both the Applied Physics Laboratory and the Whiting School of Engineering.

    Jacob has received widespread recognition for his innovative work in biomedical engineering over the past decade.  In 2017, he was awarded the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their careers.  He has been an invited speaker for diverse audiences ranging from BBC News to President Obama’s Council of Advisors on Science and Technology, has authored over 50 peer-reviewed publications, and has three patents pending in the fields of neuroprosthetics and brain-machine interfaces.

    Jacob earned a Sc.B. degree from Brown University in Bio-Electrical Engineering and a Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.

  • David Oros | Founding Partner of Gamma 3 LLC

    David Oros has been a leader in the successful development of high-technology businesses for more than 30 years. Currently, he is a founding partner of Gamma 3 LLC.  Gamma 3 provides

    early stage funding for start-up initiatives focused on IP creation, technology advancement and commercialization.  It partners with best-in-class academic institutions, inventors and entrepreneurs to create advanced technology companies in the Maryland area.

    He has raised more than $2.5 billion in six public offerings and has been recognized as a leader and visionary in several technology fields. His many awards and honors include acknowledgement as the Ernst & Young Entrepreneur of the Year; Mobile Computing Magazine’s Person of the Year for 2000, and the KPMG High Tech Entrepreneur of the Year.  He received the Westinghouse award for Leadership in Research and Development.  David also holds a U.S. patent for the airborne multi-function radar system.

    David is the Chairman and founder of Terbium Labs.  Terbium Labs is an information security company that runs Matchlight, a data intelligence system that monitors the internet for breaches of organizations’ most sensitive data.

    He is also Chairman of Gemstone Biotherapeutics LLC.  Gemstone Biotherapeutics is a leader in the field of tissue engineering and regenerative medicine.  It is developing bioengineering technology for clinical cell therapy solutions and wound healing products.

    From 2007 to 2010, David was a founding partner of Global Domain Partners, LLC, a managed futures company that uses advanced optimization modeling as a predictive tool for worldwide markets, currencies and commodities.

    From 1996 to 2006, he was the Chairman and CEO of Aether Systems, Inc., a leading provider of wireless and mobile data solutions for the financial trading systems, transportation, and public safety industries.  He built Aether Systems from a small consulting company with a handful of employees to an industry leader in high-end wireless applications.

    From 1994 to 1996, David was president of NexGen Technologies, LLC, a wireless software development company. From 1992 to 1994, he was president of the Wireless Data Group at Westinghous Electric. For a decade before that, David directed internal research at Westinghouse Electric, managing large programs in advanced airborne radar design and development.

    He currently serves on the Board of Directors for Evolving Systems, Inc., Mind-X Corporation and eNeura, Inc.  He is on the Board of Visitors for the University of Maryland Baltimore County and is the Senior Executive CEO In Residence.   He also is on the Board of Directors for Health Care for the Homeless.

  • Sherrie Perkins | Medical Device Professional

    Sherrie Perkins is a medical device professional with more than 30 years’ experience in sales, marketing, market development, business development, and commercialization strategy and

    execution. Experience includes neurology and psychiatry market segments, as well as dermatology and plastic surgery.

    Since 2000, Sherrie’s experience has focused on multiple indications within the fast-growing and expanding area of neuromodulation.  Most recently, Sherrie held several executive positions with Cyberonics, Inc. (Houston), now LivaNova, PLC (London) – including Vice President of New Business Development and Marketing and Vice President of New Ventures – Sleep Apnea.  Sherrie’s experience includes market creation, market development, and commercialization for unique medical devices in segments primarily dominated by pharmaceutical treatment options. Prior Board experience includes serving on the Board of Directors of ImThera Medical (San Diego) for six years.

    She holds a Bachelor of Science in Medical Technology from Mississippi State University and a Master of Arts in Management from Central Michigan University.

  • Jeff Mathiesen | Chief Financial Officer, Gemphire Therapeutics

    Jeff Mathiesen serves as Chief Financial Officer of Gemphire Therapeutics, a publicly traded biopharmaceutical company developing therapies for cardiometabolic disorders, including dyslipidemia and NASH.

    Mr. Mathiesen has more than 25 years of experience as Chief Financial Officer (CFO) of publicly traded companies, including three successful initial public offerings (IPOs).

    His experience encompasses a variety of highly competitive, technology-based industries in organizations with global reach and includes several M&A transactions, divestitures, organizational development and equity and debt financing. He began his career at Deloitte.

    Mr. Mathiesen also serves as Director and Audit Committee Chair of Sun BioPharma, Inc., a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, as well as Director and Audit Committee Chair of NeuroOne Medical Technologies, Inc., a publicly traded medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy.

    Mr. Mathiesen graduated summa cum laude from the University of South Dakota with a B.S. degree in Accounting.

  • Tom Brooks | Venture Partner at Camden Partners Nexus

    Tom Brooks is a Venture Partner at Camden Partners Nexus, and a Founding Partner of Anthem Energy, LLC, a private investment firm focused on North American energy investments. From

    2001 to 2008, Tom served in a variety of executive officer roles at Constellation Energy Group, Inc., including Vice Chairman & Executive Vice President. He was also President of Constellation Power Source (Constellation’s marketing and trading unit) and President of Constellation Energy Resources (a subsidiary that included non-nuclear power generation operations, wholesale and retail energy marketing and trading, and business development).

    Prior to joining Constellation, Tom was a senior member of the team that developed Goldman Sachs’ domestic power business within Goldman’s Fixed Income Currency and Commodities Division. Prior to joining Goldman, Tom was a founding partner of two successful startups: AERX, Inc., which was sold to Enron in 1992; and Elm City Management, LLC. Earlier in his career, Tom worked as a geophysicist, engaged in oil and gas exploration.

    Tom earned a B.S. from Yale University and an M.B.A. from the Yale School of Management.

Medical Advisory Board

Scientific Advisory Board

Anthony T. Barker, PhD, FIET, FIPEM | Member


Kevin Shields, MB, PhD, MRCPI | Member
Indication: The sTMS mini™ by eNeura® is indicated for the acute and prophylactic treatment of migraine headache.